Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 2.207
Filtrer
1.
Microbiome ; 12(1): 137, 2024 Jul 23.
Article de Anglais | MEDLINE | ID: mdl-39044261

RÉSUMÉ

BACKGROUND: Haematological patients exhibit immune system abnormalities that make them susceptible to viral infections. Understanding the relationship between the virome in the blood plasma of haematological patients and their clinical characteristic is crucial for disease management. We aimed to explore the presence of viral pathogens and identify close associations between viral infections and various clinical features. RESULTS: A total of 21 DNA viruses and 6 RNA viruses from 12 virus families were identified from 1383 patients. Patients with haematological diseases exhibited significantly higher diversity, prevalence, and co-detection rates of viral pathogens. During fever episodes, pathogen detection was notably higher, with Epstein-Barr virus (EBV) and Mucorales infections being the most probable culprits for fever symptoms in non-haematological patients. The detection rate of torque teno virus (TTV) significantly increases in haematological patients after transplantation and during primary lung infections. Additionally, TTV-positive patients demonstrate significantly higher absolute neutrophil counts, while C-reactive protein and procalcitonin levels are notably lower. Furthermore, TTV, cytomegalovirus, and parvovirus B19 (B19V) were found to be more prevalent in non-neutropenic patients, while non-viral pathogenic infections, such as Gram-negative bacteria and Mucorales, were more common in neutropenic patients. Pegivirus C (HPgV-C) infection often occurred post-transplantation, regardless of neutropenia. Additionally, some viruses such as TTV, B19V, EBV, and HPgV-C showed preferences for age and seasonal infections. CONCLUSIONS: Analysis of the plasma virome revealed the susceptibility of haematological patients to plasma viral infections at specific disease stages, along with the occurrence of mixed infections with non-viral pathogens. Close associations were observed between the plasma virome and various clinical characteristics, as well as clinical detection parameters. Understanding plasma virome aids in auxiliary clinical diagnosis and treatment, enabling early prevention to reduce infection rates in patients and improve their quality of life. Video Abstract.


Sujet(s)
Virus à ADN , Hémopathies , Virus à ARN , Maladies virales , Humains , Mâle , Femelle , Virus à ADN/isolement et purification , Virus à ADN/génétique , Adulte d'âge moyen , Maladies virales/sang , Maladies virales/virologie , Adulte , Hémopathies/complications , Hémopathies/sang , Virus à ARN/isolement et purification , Virome , Sujet âgé , Virus torque teno/isolement et purification , Virus torque teno/génétique , Études de cohortes , Herpèsvirus humain de type 4/génétique , Herpèsvirus humain de type 4/isolement et purification , Jeune adulte
2.
Am Fam Physician ; 110(1): 58-64, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-39028783

RÉSUMÉ

Hematologic emergencies are bleeding or clotting disorders that are hereditary or acquired and must be treated emergently to avoid significant morbidity or mortality. Patients experiencing a hematologic emergency may present with spontaneous bleeding, jaundice, petechiae, or purpura. Initial diagnostic testing should include a complete blood count. Patients who have bleeding associated with a hereditary disorder should receive clotting factor replacement before diagnostic testing. Acute chest syndrome is an uncommon but serious complication of sickle cell disease. Hemolysis caused by autoimmune disorders or iatrogenic errors from blood product transfusions has a distinct clinical presentation and requires immediate action. Severe thrombocytopenia presenting as immune or thrombotic thrombocytopenic purpura should be differentiated and treated appropriately. Disseminated intravascular coagulation and trauma coagulopathy are sometimes confused with each other, but both can cause serious injury and require unique treatments. Primary care physicians should promptly recognize patients who require emergent referral to a hematologic specialist.


Sujet(s)
Urgences , Humains , Hémopathies/thérapie , Hémopathies/diagnostic , Hémopathies/complications , Troubles de l'hémostase et de la coagulation/diagnostic , Troubles de l'hémostase et de la coagulation/thérapie , Troubles de l'hémostase et de la coagulation/étiologie , Diagnostic différentiel
3.
J Pediatr Hematol Oncol ; 46(5): e338-e347, 2024 Jul 01.
Article de Anglais | MEDLINE | ID: mdl-38857202

RÉSUMÉ

Primary mitochondrial disorders (PMDs) are known for their pleiotropic manifestations in humans, affecting almost any organ or system at any time. Hematologic manifestations, such as cytopenias and sideroblastic anemia, occur in 10% to 30% of patients with confirmed PMDs. These can be the initial presenting features or complications that develop over time. Surveillance for these manifestations allows for prompt identification and treatment. This article provides an overview of the pathophysiology underpinning the hematologic effects of mitochondrial dysfunction, discussing the 3 key roles of the mitochondria in hematopoiesis: providing energy for cell differentiation and function, synthesizing heme, and generating iron-sulfur clusters. Subsequently, the diagnosis and management of mitochondrial disorders are discussed, focusing on hematologic manifestations and the specific conditions commonly associated with them. Through this, we aimed to provide a concise point of reference for those considering a mitochondrial cause for a patient's hematologic abnormality, or for those considering a hematologic manifestation in a patient with known or suspected mitochondrial disease.


Sujet(s)
Hémopathies , Maladies mitochondriales , Humains , Maladies mitochondriales/complications , Hémopathies/sang , Hémopathies/complications , Hémopathies/anatomopathologie , Mitochondries/anatomopathologie , Hématopoïèse , Anémie sidéroblastique/diagnostic , Anémie sidéroblastique/thérapie
4.
Microbiol Spectr ; 12(7): e0429923, 2024 Jul 02.
Article de Anglais | MEDLINE | ID: mdl-38847538

RÉSUMÉ

Patients with hematological diseases are considered to be at high risk for intestinal colonization by carbapenem-resistant Gram-negative bacteria (CR-GNB). However, the epidemiological data regarding risk factors and molecular characteristics of intestinal colonized CR-GNB isolates in this population are insufficient in China. A multicenter case‒control study involving 4,641 adult patients with hematological diseases from 92 hospitals across China was conducted. Following culture of collected rectal swabs, mass spectrometry and antimicrobial susceptibility tests were performed to identify GNB species and CR phenotype. Risk factors were assessed through retrospective clinical information. Whole-genome sequencing was used to analyze the molecular characteristics of CR-GNB isolates. This trial is registered with ClinicalTrials.gov as NCT05002582. Our results demonstrated that among 4,641 adult patients, 10.8% had intestinal colonization by CR-GNB. Of these, 8.1% were colonized by carbapenem-resistant Enterobacterales (CRE), 2.6% were colonized by carbapenem-resistant Pseudomonas aeruginosa (CRPA), and 0.3% were colonized by carbapenem-resistant Acinetobacter baumannii (CRAB). The risk factors for CR-GNB colonization include male gender, acute leukemia, hematopoietic stem cell transplantation, ß-lactam antibiotic usage, and the presence of non-perianal infections within 1 week. Compared with CRPA-colonized patients, patients using carbapenems were more likely to be colonized with CRE. NDM was the predominant carbapenemase in colonized CRE. This study revealed a high CR-GNB intestinal colonization rate among adult patients with hematological diseases in China, with CRE being the predominant one. Notably, a significant proportion of CRE exhibited metallo-ß-lactamase production, indicating a concerning trend. These findings emphasize the importance of active screening for CR-GNB colonization in patients with hematological diseases.IMPORTANCECarbapenem-resistant Gram-negative bacteria (CR-GNB) has emerged as a significant threat to public health. Patients with hematological diseases are at high risk of CR-GNB infections due to their immunosuppressed state. CR-GNB colonization is an independent risk factor for subsequent infection. Understanding the risk factors and molecular characteristics of CR-GNB associated with intestinal colonization in patients with hematological diseases is crucial for empirical treatment, particularly in patients with febrile neutropenia. However, the epidemiology data are still insufficient, and our study aims to determine the intestinal colonization rate of CR-GNB, identify colonization risk factors, and analyze the molecular characteristics of colonized CR-GNB isolates.


Sujet(s)
Antibactériens , Carbapénèmes , Bactéries à Gram négatif , Infections bactériennes à Gram négatif , Hémopathies , Humains , Études cas-témoins , Mâle , Femelle , Facteurs de risque , Adulte d'âge moyen , Carbapénèmes/pharmacologie , Adulte , Infections bactériennes à Gram négatif/microbiologie , Infections bactériennes à Gram négatif/épidémiologie , Bactéries à Gram négatif/effets des médicaments et des substances chimiques , Bactéries à Gram négatif/génétique , Bactéries à Gram négatif/isolement et purification , Chine/épidémiologie , Sujet âgé , Antibactériens/pharmacologie , Hémopathies/complications , Hémopathies/microbiologie , Hémopathies/épidémiologie , Épidémiologie moléculaire , Études rétrospectives , Tests de sensibilité microbienne , Jeune adulte , Intestins/microbiologie , Adolescent , Sujet âgé de 80 ans ou plus
5.
Clin Infect Dis ; 79(1): 151-160, 2024 Jul 19.
Article de Anglais | MEDLINE | ID: mdl-38752732

RÉSUMÉ

BACKGROUND: Primary antifungal prophylaxis with mold-active azoles is used to prevent invasive fungal infections in patients with high-risk hematological disorders; however, breakthrough infections occur, and the reasons for treatment failure are still not fully understood. To help inform clinical decisions, we sought to define microbiological, clinical, and pharmacological characteristics of proven and probable breakthrough invasive fungal infections (bIFIs) in patients with high-risk hematological disorders receiving voriconazole or posaconazole prophylaxis. METHODS: We performed a systematic review of the literature following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The search strategy was last conducted on 19 April 2023. RESULTS: We assessed 5293 studies for eligibility, and 300 were selected for data extraction. These studies described 1076 cases of bIFIs occurring under voriconazole (42.5%) or posaconazole (57.5%). The most commonly found pathogens were Aspergillus (40%), Mucorales (20%), Candida (18%), and Fusarium (9%) species. Mucorales were more frequent among voriconazole-emerging cases, whereas Aspergillus and Fusarium were more prevalent among posaconazole-emerging cases. Definitive, putative, or probable antifungal resistance was found in 31% of cases. Therapeutic drug monitoring showed subtherapeutic azole concentration in 32 of 90 (36%) cases. Infection-related mortality was reported in 117 cases and reached 35%. CONCLUSIONS: In our systemic review, the most common bIFIs were aspergillosis, mucormycosis, candidiasis, and fusariosis. Antifungal resistance explains only a minority of cases. Subtherapeutic prophylaxis was frequent but rarely reported. Prospective studies are needed to better understand these infections and to establish optimal management.


Sujet(s)
Antifongiques , Hémopathies , Infections fongiques invasives , Triazoles , Voriconazole , Humains , Antifongiques/usage thérapeutique , Infections fongiques invasives/prévention et contrôle , Infections fongiques invasives/traitement médicamenteux , Voriconazole/usage thérapeutique , Hémopathies/complications , Triazoles/usage thérapeutique , Résistance des champignons aux médicaments , Aspergillus/effets des médicaments et des substances chimiques
6.
Int J Infect Dis ; 144: 107042, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38614231

RÉSUMÉ

OBJECTIVES: Whether pre-exposure prophylaxis (PrEP) with tixagevimab/cilgavimab 150 mg/150 mg (T/C) in individuals with hematologic disease (HD) may lead to a reduced risk of SARS-CoV-2 breakthrough infection (BTI)/hospitalization, or death in the Omicron era remains to be established. METHODS: An observational study included participants with HD who received PrEP. BTIs were defined as SARS-CoV-2 positivity by reverse transcription-polymerase chain reaction. The incidence of BTIs (95% CI) and of BTIs/hospitalization/death was calculated using the Kaplan-Meier method and as the number of BTIs per 100 person-years of follow-up according to the circulating variant of concern (VoC). A Poisson regression model was used to evaluate the association between the rate of incidence and circulating VoCs after controlling for demographics and clinical factors. RESULTS: We included 550 HD patients: 71% initiated T/C PrEP when BA.5 was the most prevalent, followed by XBB/EG, BA.2, and BA.1 (19%, 7%, and 3%, respectively). Overall, the 1-year incidence estimate of BTIs/hospitalization/death was 24% (18.7-29.4%). A greater risk of incident infections was observed when BA.5 and XBB/EG sub-lineages circulated (aRR 5.05 [2.17, 11.77]; P < .001 and 3.82 [1.50, 9.7]; P = 0.005, compared to BA.1, respectively). CONCLUSIONS: The 1-year incidence of SARS-CoV-2 BTIs/hospitalization/death was 24% which is in line with what was observed in other similar studies. The risk appeared to be higher when more recent Omicron sub-lineages were circulating suggesting a reduction of in vitro neutralization.


Sujet(s)
COVID-19 , Hémopathies , Prophylaxie pré-exposition , SARS-CoV-2 , Humains , Mâle , COVID-19/prévention et contrôle , COVID-19/épidémiologie , COVID-19/mortalité , Femelle , Adulte d'âge moyen , Prophylaxie pré-exposition/méthodes , Hémopathies/complications , Sujet âgé , Adulte , Incidence , Anticorps monoclonaux humanisés/usage thérapeutique , Anticorps monoclonaux humanisés/administration et posologie , Hospitalisation , Antiviraux/usage thérapeutique , Antiviraux/administration et posologie , Réinfections
8.
Brain Nerve ; 76(3): 221-229, 2024 Mar.
Article de Japonais | MEDLINE | ID: mdl-38514103

RÉSUMÉ

Many hematologic diseases can be complicated by neurological symptoms during the disease course. Hematologic diseases can contribute to strokes and neuropathies; thus, neurologists should be aware of them. Recent reports have increased of neurological side effects associated with new anticancer therapies such as immune checkpoint inhibitors and chimeric antigen receptor-T cell therapy. The relationship between hematologic diseases and neurological complications is expected to become more prevalent.


Sujet(s)
Hémopathies , Maladies du système nerveux , Accident vasculaire cérébral , Humains , Hémopathies/complications , Hémopathies/thérapie , Maladies du système nerveux/complications , Maladies du système nerveux/thérapie
9.
Article de Anglais | MEDLINE | ID: mdl-38553307

RÉSUMÉ

OBJECTIVE: This study analyzed the systemic and oral abnormalities in individuals with Kabuki syndrome (KS) that might be investigated to enhance the early diagnosis and treatment by a multidisciplinary team, minimizing the consequences to the individual's health. STUDY DESIGN: Clinical examination was conducted on 15 individuals to investigate orodental alterations such as tooth abnormalities and cleft lip and/or palate, and the patient records were also reviewed to investigate systemic diseases such as cardiopathies, infectious and immunologic diseases, nephropathies, and delayed neuropsychomotor development. RESULTS: All individuals with KS presented cleft lip and/or palate, 11 (73.34%) tooth abnormalities, 5 (33.34%) congenital cardiopathies, 12 (80%) infectious or immunologic diseases, 1 (6.67%) nephropathy, and 14 (93.34%) had an intellectual disability. CONCLUSION: Individuals with KS often have dental anomalies such as hypodontia, cleft or palate, and systemic disorders such as congenital heart disease and infectious diseases. Intellectual disability is present in most cases. These alterations should be investigated as early as possible to prevent the increase in morbidity in these individuals.


Sujet(s)
Malformations multiples , Face/malformations , Maladies vestibulaires , Humains , Femelle , Mâle , Maladies vestibulaires/complications , Enfant , Enfant d'âge préscolaire , Adolescent , Malformations dentaires , Adulte , Déficience intellectuelle/complications , Nourrisson , Fente palatine/complications , Hémopathies/complications
10.
Leuk Lymphoma ; 65(7): 997-1002, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38498769

RÉSUMÉ

Corynebacterium is generally considered a contaminant in clinical practice. However, it may cause bacteremia in patients with hematologic disorders, and factors that contribute to its mortality are unclear. A case series and systematic literature review identified 96 cases of Corynebacterium bacteremia inhematologic disorderpatients. The median age was 50.5 years (range: 2-93 years), with 79 (82%) patients 18 years or older, and 64 (67%) patients male. Most cases involved hematologic malignancies, and neutropenia was observed in approximately 75% cases. The most common sites of infection/symptoms were skin and soft tissue, respiratory, and catheter-related bloodstream infection. The infection-related mortality was 23%, and univariate analysis showed that age, respiratory infection/symptoms, and source control were significantly associated with infection-related mortality. Multivariate analysis indicates that infection-related mortality was significantly reduced by source control (OR: 0.24, 95% CI: 0.06-0.97, p = 0.046). Therefore, when Corynebacterium infections are suspected, early source control should be considered.


Sujet(s)
Bactériémie , Infections à Corynebacterium , Corynebacterium , Hémopathies , Humains , Bactériémie/microbiologie , Bactériémie/diagnostic , Bactériémie/étiologie , Infections à Corynebacterium/complications , Infections à Corynebacterium/diagnostic , Infections à Corynebacterium/microbiologie , Corynebacterium/isolement et purification , Sujet âgé , Adulte , Adulte d'âge moyen , Sujet âgé de 80 ans ou plus , Mâle , Adolescent , Hémopathies/complications , Hémopathies/microbiologie , Jeune adulte , Femelle , Enfant , Enfant d'âge préscolaire , Facteurs de risque
11.
Expert Rev Hematol ; 17(4-5): 135-143, 2024.
Article de Anglais | MEDLINE | ID: mdl-38465408

RÉSUMÉ

BACKGROUND: To develop and internally validate a prediction model for identifying patients with hematologic diseases of fall risk. RESEARCH DESIGN AND METHODS: This is a prospective cohort study from a prospective collection of data for 6 months. We recruited 412 patients with hematologic diseases in medical institutions and home environment of China. The outcome of the prediction model was fall or not. These variables were filtered via univariable logistic analysis, LASSO, and multivariable logistic analysis. We adopt an internal validation method of K-fold cross validation. The area under the ROC curve and the H-L test were used to evaluate the discrimination and calibration of the model. RESULTS: Five influencing factors were identified multivariable logistic regression analysis. The established model equation is as follows: the H-L goodness-of-fit test of the model p > 0.05. The area under the ROC curve of train is 0.957 (95% CI: 0.936 ~ 0.978), and the area under the ROC curve of test is 0.962 (95% CI: 0.884 ~ 1), so the model calibration and discriminant validity are good. CONCLUSION: Our equation has good sensitivity and specificity in predicting the fall risk of patients with hematologic diseases, and has certain positive significance for clinical assessment of their fall risk. TRIAL REGISTRATION NUMBER: ChiCTR2200063940.


Sujet(s)
Chutes accidentelles , Hémopathies , Humains , Hémopathies/diagnostic , Hémopathies/complications , Femelle , Mâle , Adulte d'âge moyen , Sujet âgé , Études prospectives , Courbe ROC , Études de cohortes , Adulte , Facteurs de risque , Appréciation des risques , Chine/épidémiologie , Sujet âgé de 80 ans ou plus
13.
J Intellect Disabil Res ; 68(2): 173-180, 2024 Feb.
Article de Anglais | MEDLINE | ID: mdl-37921399

RÉSUMÉ

BACKGROUND: Understanding the specific neurobehavioural profile of rare genetic diseases enables clinicians to provide the best possible care for patients and families, including prognostic and treatment advisement. Previous studies suggested that a subset of individuals with Kabuki syndrome (KS), a genetic disorder causing intellectual disability and other neurodevelopmental phenotypes, have attentional deficits. However, these studies looked at relatively small numbers of molecularly confirmed cases and often used retrospective clinical data instead of standardised assessments. METHODS: Fifty-five individuals or caregivers of individuals with molecularly confirmed KS completed assessments to investigate behaviour and adaptive function. Additionally, information was collected on 23 unaffected biological siblings as controls. RESULTS: Attention Problems in children was the only behavioural category that, when averaged, was clinically significant, with the individual scores of nearly 50% of the children with KS falling in the problematic range. Children with KS scored significantly higher than their unaffected sibling on nearly all behavioural categories. A significant correlation was found between Attention Problems scores and adaptive function scores (P = 0.032), which was not explained by lower general cognitive ability. CONCLUSIONS: We found that the rates of children with attentional deficits are much more elevated than would be expected in the general population, and that attention challenges are negatively correlated with adaptive function. When averaged across KS participants, none of the behavioural categories were in the clinically significant range except Attention Problems for children, which underscores the importance of clinicians screening for attention deficit hyperactivity disorder (ADHD) in children with KS.


Sujet(s)
Malformations multiples , Face/malformations , Hémopathies , Déficience intellectuelle , Maladies vestibulaires , Enfant , Humains , Études rétrospectives , Hémopathies/complications , Hémopathies/génétique
14.
Am J Med Genet A ; 194(2): 268-278, 2024 Feb.
Article de Anglais | MEDLINE | ID: mdl-37815018

RÉSUMÉ

Kabuki syndrome (KS) is characterized by growth impairment, psychomotor delay, congenital heart disease, and distinctive facial features. KMT2D and KDM6A have been identified as the causative genes of KS. Craniosynostosis (CS) has been reported in individuals with KS; however, its prevalence and clinical implications remain unclear. In this retrospective study, we investigated the occurrence of CS in individuals with genetically diagnosed KS and examined its clinical significance. Among 42 individuals with genetically diagnosed KS, 21 (50%) exhibited CS, with 10 individuals requiring cranioplasty. No significant differences were observed based on sex, causative gene, and molecular consequence among individuals with KS who exhibited CS. Both individuals who underwent evaluation with three-dimensional computed tomography (3DCT) and those who required surgery tended to exhibit cranial dysmorphology. Notably, in several individuals, CS was diagnosed before KS, suggesting that CS could be one of the clinical features by which clinicians can diagnose KS. This study highlights that CS is one of the noteworthy complications in KS, emphasizing the importance of monitoring cranial deformities in the health management of individuals with KS. The findings suggest that in individuals where CS is a concern, conducting 3DCT evaluations for CS and digital impressions are crucial.


Sujet(s)
Malformations multiples , Craniosynostoses , Face/malformations , Hémopathies , Maladies vestibulaires , Humains , Études rétrospectives , Prévalence , Malformations multiples/diagnostic , Malformations multiples/épidémiologie , Malformations multiples/génétique , Hémopathies/complications , Hémopathies/diagnostic , Hémopathies/épidémiologie , Maladies vestibulaires/diagnostic , Maladies vestibulaires/épidémiologie , Maladies vestibulaires/génétique , Craniosynostoses/complications , Craniosynostoses/diagnostic , Craniosynostoses/épidémiologie , Histone Demethylases/génétique , Mutation
15.
Cancer ; 130(1): 41-50, 2024 01 01.
Article de Anglais | MEDLINE | ID: mdl-37658645

RÉSUMÉ

BACKGROUND: Managing SARS-CoV-2 infection in frail and immunosuppressed patients still represents an open challenge, but, starting from the phase 3 PROVENT study, prophylaxis with tixagevimab-cilgavimab has improved the approach in this category of patients, guaranteeing a better outcome and inferior mortality. Real-life data in a heterogeneous cohort are few. METHODS: The aim of this study is to evaluate the benefit of prophylaxis with tixagevimab-cilgavimab in a cohort of 202 patients affected by different hematological diseases (lymphoproliferative, myeloproliferative, autoimmune, patients recently receiving a bone marrow transplant), active (with ongoing treatment), or in watch-and-wait strategy, followed in our center, during a median follow-up of 249 (45-325) days. RESULTS: An incidence of 44 breakthrough infections (21.8%) is reported, with no treatment-related adverse effects. Age ≥70 years, ongoing treatment (above all with monoclonal antibodies), baseline lymphoproliferative disorders, and prior virus exposure are identified as risk factors related to subsequent infection (p < 0.05). Moreover, the incidence is higher in low/nonresponse to prior vaccination (p = .002). Patients treated with tixagevimab-cilgavimab had a mild course of the infection and a reduction of the duration compared with preprophylaxis infection (11 vs. 15 days, p < .001). The concurrent treatment with anti-CD20 monoclonal antibodies and B-non-Hodgkin lymphoma still confers a higher duration of infection despite prophylaxis. No deaths attributable to the infection occurred. CONCLUSION: Prophylaxis treatment seems to be a valid and safe strategy, although not preventing breakthrough infection, but the severe complications associated with the infection and the possible delays in administering lifesaving therapies from long positivity.


Sujet(s)
COVID-19 , Effets secondaires indésirables des médicaments , Hémopathies , Humains , Sujet âgé , Réinfections , SARS-CoV-2 , Anticorps monoclonaux , Hémopathies/complications
16.
Zh Nevrol Psikhiatr Im S S Korsakova ; 123(9. Vyp. 2): 33-42, 2023.
Article de Russe | MEDLINE | ID: mdl-37942970

RÉSUMÉ

OBJECTIVE: To assess risk factors (RF) and severity grade of Posterior reversible encephalopathy syndrome (PRES) in children with hematological diseases. MATERIAL AND METHODS: We analyzed cases of PRES in children during chemotherapy (CT) and after allogeneic hematopoietic stem cell transplantation (allo-HSCT). We estimated the following RF: arterial hypertension, steroid therapy, CT, immunosuppressive therapy (IST), infection and renal injury. RESULTS: Thirty-five cases of PRES occurred in 32 patients (8 after allo-HSCT and 27 during CT) were included in this study. In the most of cases (94.3%), there were 2 and more RF. An increase in blood pressure level (88.6%), CT and IST (82.8%) administration, steroid therapy (71.4%) were the most significant for PRES development. Infectious process and the decline in renal function played a lesser role in this syndrome (31.4% and 14%). At the initial presentation of PRES, there were seizures (94.3%), a decrease of consciousness (28.6%), headache, vision disturbances and stomachache (20%). In the most of cases (91.4%), the 2nd and 3d grade according to the Common Terminology Criteria for Adverse Events (CTCAE 5.0) were observed. Brain magnetic resonance imaging (MRI) revealed the vasogenic edema of temporal (88.6%), occipital (74.3%), frontal (40%) lobes and the cerebellum (22.9%) more often than the cytotoxic edema (p=0.03). The cytotoxic edema was observed in the thalamus and the basal ganglia (2.9%) more often than in other parts of the brain (p<0.01). CONCLUSION: The majority of PRES cases are caused by more than two RF. Arterial hypertension does not have a leading role among its causes. There is a significant correlation between the grade of PRES according to CTCAE 5.0 score and RF number (p<0.05).


Sujet(s)
Hémopathies , Hypertension artérielle , Leucoencéphalopathie postérieure , Humains , Enfant , Leucoencéphalopathie postérieure/imagerie diagnostique , Leucoencéphalopathie postérieure/étiologie , Hypertension artérielle/complications , Imagerie par résonance magnétique/méthodes , Hémopathies/complications , Oedème/complications , Stéroïdes
17.
Chirurgie (Heidelb) ; 94(12): 987-993, 2023 Dec.
Article de Allemand | MEDLINE | ID: mdl-37947801

RÉSUMÉ

BACKGROUND: Splenic surgery in hematological disorders requires a well-weighted decision on the indications because the medical treatment has rapidly changed in recent years due to new pharmaceutical approaches. OBJECTIVE: Summary of the indications, surgical procedures and perioperative management regarding operative interventions on the spleen in hematological disorders. MATERIAL AND METHODS: Selective literature search and summary of reviews and guideline recommendations. RESULTS: In hematological disorders surgical procedures of the spleen (splenectomy and partial splenectomy) are an important part of the repertoire in the treatment. In recent years the indications for surgery have become narrower because of new forms of medicinal treatment. Especially in hereditary spherocytosis, immune thrombocytopenia and symptomatic splenomegaly and hypersplenism it is still of importance. The minimally invasive splenectomy is regarded as the gold standard. The spleen has an important immune and sequestration function, therefore preoperative and postoperative infectious and thromboembolic events have to be anticipated and prevented. A close interdisciplinary cooperation with hematologists is essential for an optimal outcome of patients. CONCLUSION: The minimally invasive splenectomy and partial splenectomy are part of the surgical repertoire in the diagnostics and treatment of hematological disorders. Because of novel medicinal approaches the therapeutic protocols are continuously changing. A close cooperation with hematologists is important for the optimal evaluation of the indications and the perioperative management.


Sujet(s)
Hémopathies , Rate , Humains , Résultat thérapeutique , Rate/chirurgie , Hémopathies/chirurgie , Hémopathies/complications , Splénectomie/effets indésirables , Splénectomie/méthodes , Splénomégalie/étiologie , Splénomégalie/chirurgie
18.
Int J Hematol ; 118(6): 726-730, 2023 Dec.
Article de Anglais | MEDLINE | ID: mdl-37848665

RÉSUMÉ

The mortality risk factors in B. cereus bacteremia in hematologic disorders are still unknown. In this study, patients with B. cereus bacteremia in hematologic disorders were selected in St. lukes international hospital and from electronic databases. A total of 176 patients [median age, 41 years (3-88 years); 99 (56%) males] were included. Of these patients, 141 (80%) had acute leukemia, and 93 (53%) died. Univariate analysis showed that neutropenia, CNS, gastrointestinal, and respiratory infections/symptoms were significantly associated with infection-related death. Meanwhile, glycopeptide use and management with source control were protective factors. Multivariate logistic regression analysis showed that infection-related death was significantly associated with CNS [odds ratio (OR): 3.49, 95% confidence interval (CI) 1.25-9.80], gastrointestinal (OR: 5.22, 95% CI 1.82-8.99), and respiratory infections/symptoms (OR: 8.98, 95% CI 1.62-49.9), as well as glycopeptide use (OR: 0.10, 95% CI 0.03-0.31) and source control (OR: 0.11, 95% CI 0.03-0.37). In conclusion, early glycopeptide administration and source control should be performed upon detection of infections suspicious for B. cereus.


Sujet(s)
Bactériémie , Infections bactériennes à Gram positif , Hémopathies , Infections de l'appareil respiratoire , Mâle , Humains , Adulte , Femelle , Bacillus cereus , Hémopathies/complications , Facteurs de risque , Infections de l'appareil respiratoire/complications , Glycopeptides
19.
Zhongguo Shi Yan Xue Ye Xue Za Zhi ; 31(5): 1556-1562, 2023 Oct.
Article de Chinois | MEDLINE | ID: mdl-37846716

RÉSUMÉ

OBJECTIVE: To analyze the pathogenic bacterial spectrum, drug resistance, and risk factors associated with multidrug-resistant bacterial infection and mortality in patients with hematologic diseases complicated by bloodstream infections, so as to provide reference for rational drug use and improving prognosis. METHODS: Positive blood culture specimens of patients with hematologic diseases in two Class A tertiary hospitals of Shanxi province from January 2019 to December 2021 were retrospectively analyzed. Pathogen distribution, drug resistance and outcomes of patients with bloodstream infection were investigated, then the multivariate logistic analysis was performed to analyze the risk factors of multidrug-resistant bacterial infection and factors affecting prognosis. RESULTS: 203 strains of pathogens were identified, mainly Gram-negative bacteria (GNB) (69.46%, 141/203), of which Escherichia coli (E.coli) had the highest incidence (41.13%, 58/141), followed by Klebsiella pneumoniae (20.57%, 29/141) and Pseudomonas aeruginosa (12.77%, 18/141). Extended-spectrum beta-lactamase (ESBL)-producing E.coli and Klebsiella pneumoniae were 46.55% (27/58) and 37.93% (11/29), respectively. Carbapenem-resistant Gram-negative bacteria accounted for 10.64% (15/141). And Gram-positive bacteria accounted for 27.59% (56/203), Staphylococcus epidermidis, Streptococcus pneumoniae, and Staphylococcus aureus were the most frequently isolated pathogen among Gram-positive bacteria (14.29%, 12.50% and 10.71%, respectively), of which methicillin-resistant Staphylococcus aureus accounted for 33.33% (2/6), coagulase-negative staphylococci accounted for 87.50% (7/8), without vancomycin- or linezolid-resistant strain. Additionally, fungi accounted for 2.95% (6/203), all of which were Candida. Multidrug-resistant Gram-negative bacteria (MDR-GNB) accounted for 53.90% (76/141). Duration of neutropenia >14 days was a risk factor for developing MDR-GNB infection. The 30-day all-cause mortality was 10.84%. Multivariate logistic regression analysis showed that the significant independent risk factors for mortality were age≥60 years (P <0.01, OR =5.85, 95% CI: 1.80-19.07) and use of vasopressor drugs (P <0.01, OR =5.89, 95% CI: 1.83-18.94). CONCLUSION: The pathogenic bacteria of bloodstream infection in patients with hematological diseases are widely distributed, and the detection rate of multidrug-resistant bacteria is high. The clinicians should choose suitable antibiotics according to the results of bacterial culture and antibiotic susceptibility test.


Sujet(s)
Bactériémie , Résistance bactérienne aux médicaments , Hémopathies , Staphylococcus aureus résistant à la méticilline , Sepsie , Humains , Adulte d'âge moyen , Bactériémie/étiologie , Bactériémie/microbiologie , Bactériémie/mortalité , Bactéries/isolement et purification , Résistance aux substances , Bactéries à Gram négatif , Hémopathies/complications , Études rétrospectives , Facteurs de risque , Sepsie/étiologie , Sepsie/microbiologie , Sepsie/mortalité
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE